Eli Lilly and Company announced in December that its next-generation weight loss drug retatrutide helped patients shed more pounds than any other similar weight-loss drug during a late-stage trial.
Patients taking the once-weekly drug over the course of 68 weeks lost nearly 29 percent of their body weight, whereas patients taking semaglutide drugs such as Ozempic or Wegovy previously lost only 16 percent.